ACD680 / AlzeCure, Eli Lilly - LARVOL DELTA

AlzeCure Pharma has signed a collaboration and out‑licensing agreement with Eli Lilly granting the US company global rights to the Alzheimer’s project Alzstatin ACD680. (Pharmacy Times) - "The deal includes a $10 million USD upfront payment, development and commercial milestones, and tiered mid‑single digit royalties. AlzeCure said the total value of the agreement, excluding royalties, may exceed $1 billion USD."

Licensing / partnership • Alzheimer's Disease

AlzeCure Pharma to Present at Redeye Alzheimer's Theme Event on April 9 (Yahoo Finance) - "...CEO Martin Jönsson and CSO Johan Sandin will present the company and its project portfolio within Alzheimer's. The presentation will be followed by a Q&A session moderated by Redeye's analysts."

Clinical • Alzheimer's Disease

AlzeCure presents new data on its preventive treatment Alzstatin at the Alzheimer's conference AD/PD 2023 (Market Screener) - "AlzeCure Pharma AB...today announced that the company's presentation at the Alzheimer's conference AD/PD 2023 is now available in its entirety on the company's website. The presentation contains new preclinical data with the drug candidate Alzstatin AC-0027875, which is being developed as a preventive and disease-modifying treatment of Alzheimer’s disease....The presentation includes new preclinical results with AC-0027875, AlzeCure's potent small molecule GSM. The candidate drug reduces the production of toxic Aβ42, which creates harmful plaques in the brain, both in human cell systems and in vivo models, where it can reduce levels by over 50%. The substance also shows a very high concentration in the brain, which is a big advantage for these small molecule drugs that can more easily cross the blood-brain barrier."

Preclinical • Alzheimer's Disease • CNS Disorders

IN VITRO AND IN VIVO PROFILE OF AC-0027875, A NOVEL GAMMA-SECRETASE MODULATOR FOR THE PREVENTION AND TREATMENT OF ALZHEIMER´S DISEASE (ADPD 2023) - "The GSM AC -0027875 shows a promising in vitro and in vivo profile and therefore is a su itable candidate for further development for the prevention and treatment of Alzheimer´s disease."

Preclinical • Alzheimer's Disease • CNS Disorders • Aβ42

AlzeCure Gets Late-Breaking Abstract on New Data with Its Alzheimer Project Alzstatin Accepted At AD/PD 2023 (Yahoo Finance) - “AlzeCure Pharma…today announced that an abstract with new preclinical Alzstatin data has been accepted for presentation at the Alzheimer conference AD/PD 2023, which will be held in Gothenburg, Sweden, on March 28 - April 1….The presentation includes new preclinical results with AlzeCure's compound AC-0027875, which is a new potent small molecule gamma-secretase modulator (GSM) and part of AlzeCure's research platform Alzstatin®. In the studies, the substance exhibits a high concentration in the brain which results in powerful effects on the production of the protein amyloid-beta, where the amount of toxic Aβ42 is reduced by over 50%. AlzeCure's GSM exhibits several key properties that make it suitable as a preventive or disease-modifying treatment for Alzheimer's disease.”

Preclinical • Alzheimer's Disease • CNS Disorders

AC-0027875, A NOVEL GAMMA-SECRETASE MODULATOR FOR THE TREATMENT OF ALZHEIMER’S DISEASE. (CTAD 2022) - "The newly developed GSM AC-0027875 is a promising candidate for further development for the treatment of Alzheimer´s disease. All abstracts are embargoed until the day and time of presentation at the CTAD Conference S83"

Alzheimer's Disease • Amyloidosis • CNS Disorders • APP

New data on Alzstatin for preventive treatment against Alzheimer's presented at Alzheimer's conference CTAD (Market Screener) - "AlzeCure Pharma AB...announced that the company's presentation of its research platform Alzstatin, which was presented at the scientific conference CTAD in San Francisco, is now available in its entirety on the company's website....The presentation included results with AC-0027875, a new potent small molecule gamma-secretase modulator (GSM) and part of AlzeCure's research platform Alzstatin, which exhibited potent effects on toxic Aβ42 production in cells and animals. Data showed reductions of over 50% in vivo with a rapid onset of effect and good duration. AC-0027875 also had good pharmacokinetic properties with high penetration across the blood-brain barrier resulting in high concentration of the substance in the target organ, the brain."

Preclinical • Alzheimer's Disease • CNS Disorders

AlzeCure Presents New Data with its Preventive Treatment Alzstatin at the Alzheimer Conference CTAD (BioSpace) - “AlzeCure Pharma AB…announced that an abstract with new preclinical Alzstatin data has been accepted for presentation at the annual Alzheimer conference CTAD, Clinical Trials in Alzheimer's Disease, which this year is being held in San Francisco on November 29 - December 2….The presentation includes new preclinical results with AlzeCure's compound AC-0027875, which is a new potent small molecule gamma-secretase modulator (GSM) and part of AlzeCure's research platform Alzstatin®. The substance exhibits potent effects on the production of toxic Aβ42 and reduces levels by over 50% in vivo. GSM's represents a promising class of Aβ42-lowering anti-amyloidogenic substances for the treatment of Alzheimer's disease.”

Preclinical • Alzheimer's Disease • CNS Disorders

AlzeCure Publishes New Data on Alzstatin from Alzheimer Conference (BioSpace) - “AlzeCure Pharma AB…announced that the company's presentation regarding the research platform Alzstatin at the Alzheimer's conference 2nd Swedish Meeting for Alzheimer Research…The results show that the substance, AC-0027875, effectively crosses the blood-brain barrier and reaches the target organ, i.e. the brain, in high concentrations, which is essential for a good pharmacological effect. Furthermore, data show that the potent effect of the substance on γ-secretase led to a reduction in the amount of harmful Aβ42 by more than 50 percent.”

Preclinical • Alzheimer's Disease • CNS Disorders